| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE40000 | WOODWARD | Method of treatment for decreasing mortality resulting from congestive heart failure |
Jun, 2015
(8 years ago) | |
|
USRE40000 (Pediatric) | WOODWARD | Method of treatment for decreasing mortality resulting from congestive heart failure |
Dec, 2015
(8 years ago) | |
Coreg is owned by Woodward.
Coreg contains Carvedilol.
Coreg has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Coreg are:
- USRE40000
- USRE40000*PED
Coreg was authorised for market use on 29 May, 1997.
Coreg is available in tablet;oral dosage forms.
Coreg can be used as decreasing mortality caused by congestive heart failure.
The generics of Coreg are possible to be released after 07 December, 2015.
Drugs and Companies using CARVEDILOL ingredient
Market Authorisation Date: 29 May, 1997
Treatment: Decreasing mortality caused by congestive heart failure
Dosage: TABLET;ORAL
How can I launch a generic of COREG before it's drug patent expiration?
More Information on Dosage
COREG family patents
